

Request for Proposal

Opportunity for collaboration in the **NEUROIMMUNOLOGY/NEUROINFLAMMATORY** area

A large Japanese pharmaceutical company is currently seeking for an academia to collaborate in the neuroimmunology/neuroinflammatory area. The company is seeking for ideas based on unpublished data or filed but unpublished patents. The company values research proposals based on patient/human data. The partnership includes collaborative research/development, out-licensing of asset or technology and possible funding opportunity depending on the term.

Target disorder:

- Alzheimer's disease
- Parkinson's disease
- Frontotemporal lobar degeneration
- Amyotrophic Lateral Sclerosis
- Huntington's disease
- Narcolepsy
- Autism
- Depression
- Schizophrenia
- Bipolar disorder

Evaluation items:

- Summary of idea to partner with a pharmaceutical company
- Disease area of possible application of the idea (more than one can be proposed)
- Mechanism of action if available
- Stage of the asset (if the idea is an asset out-license)
- Summary of human-based findings in relation to the proposal
- Summary of preclinical (non-human) findings in relation to the proposal
- Any strengths or differentiating points of the idea, such as novelty or feasibility (if available)
- IP status

Proposals also include the following items:

- Overview of the research team and profile of the key researcher
- Development plan (if available)
- Desired collaboration type (if any)

Responding to this request:

- By submitting a proposal, you declare that the proposal does not and will not contain any kind of confidential information.
- Your Proposal should be an executive summary (free format, within 5 pages, including figures and tables) in English.

Application method, period, inquiry:

- Apply and make inquiries via the e-mail at **myamamoto@japantechnologygroup.com**
- Heading "Attention: Mitsu Yamamoto, Japan Technology Group (JTG)"
- Closing date for application: **March 15th, 2018**
- JTG will provide a feedback for all applicants by the end of April, 2018 by e-mail